ABOUT
Welcome to the 6th RAS-Targeted Drug Development Summit!
As recent advances in next-generation modalities to target mutant RAS progress from the bench to the clinic, the 6th RAS-Targeted Drug Development Summit returned with 3 days of jam-packed insights to address your burning questions which included:
 |
How to overcome challenges associated with selectively targeting KRAS G12D and G12V? |
|
How to rationally design small molecules and cell therapies beyond covalent inhibitors? |
|
How to establish robust preclinical assays and models for evaluating the efficacy of RAS-targeting drugs outside NSCLC? |
|
How to inform vertical or parallel pathway targeting agents to synergize as a combination therapy? |
|
How to anticipate and address potential regulatory hurdles when translating into the clinic? |
|
How to accurately inform disease-specific and tailored RAS-targeted treatment regimes? |
Uniting 150+ of your biopharma and academic peers from Early Discovery, Translational Oncology and Clinical Development this end-to-end meeting was your unrivalled opportunity to foster critical conversations and navigate the cutting-edge treatments at the cusp of improving the standard of patient care for oncology patients.
4 Reasons People Attended in 2024:
Discover the latest modalities beyond covalent inhibitors paving the way for best-in-class, boasting improved depth and durability of response, with talks on novel RAS-targeting PROTACs, molecular glues, cell therapies and vaccines from Astellas Pharma, Nested Therapeutics and Elicio Therapeutics
De-risk the discovery and clinical efforts that are exploiting parallel, vertical, and non-canonical targets for single agent or combination therapy, including the development of MEK/pan-RAF, ULK1/2 and ERK inhibitors with insights from Verastem Oncology, Kura Oncology & BioMed Valley Discoveries
Explore the latest translational and clinical developments in next-generation RAS-inhibitors as biotech and pharma, including Frontier Medicines, Loxo@Lilly and Roche, race to develop G12C(ON), G12D and G12V inhibitors with improved potency and selectivity for best-in-class therapeutics
Witness the surge in innovative strides from Revolution Medicine, Amgen, GenFleet Therapeutics, Novartis & Frontier Medicines as they discover, validate and translate pan-RAS inhibitors and make broad spectrum coverage of heterogenous mutation points a reality
